

CLAIM AMENDMENTS

1. (currently amended) A Severe Acute Respiratory Syndrome (SARS) neutralizing monoclonal antibody selected from the group consisting of F26G3, F26G7, F26G9, F26G10, F26G18 and F26G19 having a light chain amino acid sequence as set forth in SEQ ID No 14 and a heavy chain amino acid sequence as set forth in SEQ ID No. 5.

2. cancelled

3. (currently amended) A kit comprising ~~at least one monoclonal antibody selected from the group consisting of: F26G1, F26G2, F26G4, F26G5, F26G6, F26G8, F26G12, F26G13, F26G14, F26G16, F26G17, F26G3, F26G7, F26G9, F26G10, G26G18 and F26G19~~ having a light chain amino acid sequence as set forth in SEQ ID No 14 and a heavy chain amino acid sequence as set forth in SEQ ID No. 5.

4. (currently amended) A pharmaceutical composition comprising a Severe Acute Respiratory Syndrome (SARS) neutralizing monoclonal antibody selected from the group consisting of F26G3, F26G7, F26G9, F26G10, F26G18 having a light chain amino acid sequence as set forth in SEQ ID No 14 and a heavy chain amino acid sequence as set forth in SEQ ID No. 5; F26G19 and combinations thereof and a suitable excipient.

5. (currently amended) A method of preparing a chimeric antibody comprising:

introducing an expression vector which comprises a nucleic acid encoding a constant region domain of a human light or heavy chain and a nucleic acid encoding ~~a light chain variable region selected from the group consisting of G1-light (SEQ ID No. 34); G3-light (SEQ ID No. 28); G6-light (SEQ ID No. 35); G7-light (SEQ ID No. 29); G8-light (SEQ ID No. 36); G9-light (SEQ ID No. 30); G10-light (SEQ ID No. 31); G18-light (as set forth in SEQ ID No. 32) and G19-light (SEQ ID No. 33) or a heavy chain-variable region selected from the group consisting of G1-heavy (SEQ ID No. 25); G3-heavy (SEQ ID No. 19); G6-heavy (SEQ ID No. 26); G7-heavy (SEQ ID No. 20); G8-heavy (SEQ ID No. 27); G9-light (SEQ ID No. 21); G10-light (SEQ ID No.~~

~~22); G18-light~~heavy (as set forth in SEQ ID No. 23) and ~~G19-light (SEQ ID No. 24)~~
into a suitable host cell;

growing the host cell under conditions promoting expression of the
chimeric antibody; and

recovering the chimeric antibody.

6. (currently amended) A method of preparing a humanized antibody
comprising:

providing a nucleic acid comprising a light chain variable region selected
from the group consisting of ~~G1-light (SEQ ID No. 34); G3-light (SEQ ID No. 28); G6-~~
~~light (SEQ ID No. 35); G7-light (SEQ ID No. 29); G8-light (SEQ ID No. 36); G9-light~~
~~(SEQ ID No. 30); G10-light (SEQ ID No. 31); G18-light (as set forth in SEQ ID No. 32)~~
and ~~G19-light (SEQ ID No. 33)~~ or a heavy chain variable region selected from the
group consisting of ~~G1-heavy (SEQ ID No. 25); G3-heavy (SEQ ID No. 19); G6-heavy~~
~~(SEQ ID No. 26); G7-heavy (SEQ ID No. 20); G8-heavy (SEQ ID No. 27); G9-light~~
~~(SEQ ID No. 21); G10-light (SEQ ID No. 22); G18-light~~heavy (as set forth in SEQ ID
No. 23) and ~~G19-light (SEQ ID No. 24);~~

modifying said nucleic acid such that at least one but fewer than about
30 of the amino acid residues of said variable region has been changed and/or
deleted without disrupting antigen binding;

introducing said nucleic acid into a suitable host cell;

growing the host cell under conditions promoting expression of the
humanized antibody; and

recovering the humanized antibody.

7. (previously presented) A pharmaceutical composition comprising a
chimeric antibody of claim 5 and a suitable carrier.

8. (previously presented) A pharmaceutical composition comprising a
humanized antibody of claim 6 and a suitable carrier.

9. A method of preparing a vaccine comprising:

recovering from a preparation of live, attenuated or recombinant Severe
Acute Respiratory Syndrome (SARS) virus, antigens recognized by ~~one or more~~

~~monoclonal antibody antibodies selected from the group consisting of F26G1, F26G2, F26G4, F26G5, F26G6, F26G8, F26G12, F26G13, F26G14, F26G16, F26G17, F26G3, F26G7, F26G9, F26G10, G26G18 having a light chain amino acid sequence as set forth in SEQ ID No 14 and a heavy chain amino acid sequence as set forth in SEQ ID No. 5 and F26G19.~~

10. (currently amended) A nucleic acid molecule encoding a peptide comprising a light chain variable region selected from the group consisting of G1-light (SEQ ID No. 34); G3-light (SEQ ID No. 28); G6-light (SEQ ID No. 35); G7-light (SEQ ID No. 29); G8-light (SEQ ID No. 36); G9-light (SEQ ID No. 30); G10-light (SEQ ID No. 31); G18-light (having a nucleotide sequence as set forth in SEQ ID No. 32) and G19-light (SEQ ID No. 33) or a heavy chain variable region selected from the group consisting of G1-heavy (SEQ ID No. 25); G3-heavy (SEQ ID No. 19); G6-heavy (SEQ ID No. 26); G7-heavy (SEQ ID No. 20); G8-heavy (SEQ ID No. 27); G9-light (SEQ ID No. 21); G10-light (SEQ ID No. 22); G18-light heavy (having a nucleotide sequence as set forth in SEQ ID No. 23) and G19-light (SEQ ID No. 24).